CompletedNCT00735709
Vortioxetine or placebo for major depression
About this title
Read the official source — NCT00735709Researchers compared Vortioxetine and placebo to find out how the approaches affected depression symptoms in adults with depression.
Medication studyAges 18–75Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Vortioxetine and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Elizabeth Vale and 47 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 560
- Sponsor
- Takeda
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Australia, France, United Kingdom, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00735709
- Official title
Show the full official title
A Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Elizabeth Vale, Australia · Southport, Australia · Litoměřice, Czechia
47 more locations
- Lnáře, Czechia
- Prague, Czechia
- Bully-les-Mines, France
- Marseille, France
- Strasbourg, France
- Bochum, Germany
- Chemnitz, Germany
- Dillingen, Germany
- Hüttenberg, Germany
- Leipzig, Germany
- München, Germany
- Nuremberg, Germany
- Osnabrück, Germany
- Rodgau, Germany
- Westerstede, Germany
- Leipaja, Latvia
- Riga, Latvia
- Sigulda, Latvia
- Strenči, Latvia
- Vilnius, Lithuania
- Kuala Lumpur, Malaysia
- Wildervank, Netherlands
- Bialystok, Poland
- Leszno, Poland
- Skórzewo, Poland
- Torun, Poland
- Tuszyn, Poland
- Moscow, Russia
- Saint Petersburg, Russia
- Stavropol, Russia
- Tomsk, Russia
- Velikiy Novgorod, Russia
- Durban, South Africa
- Noordheuwel, South Africa
- Pretoria, South Africa
- Bucheon-si, South Korea
- Namdong-gu, South Korea
- Seoul, South Korea
- Lin-Yan District, Taiwan
- Dnipro, Ukraine
- Kharkiv, Ukraine
- Luhansk, Ukraine
- Simferopol, Ukraine
- Bath, United Kingdom
- Bolton, United Kingdom
- Czechia
- Russia
Questions about this study
What did researchers investigate?
Researchers compared Vortioxetine and placebo to find out how the approaches affected depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Takeda.
Did this study involve medication?
Yes. The study involved medication, including Vortioxetine and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
